Peter Stenvinkel: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
Next edit →
Content deleted Content added
VisualWikitext
←Created page with '{{Infobox academic | name = Peter Stenvinkel | image = | birth_date = {{birth date and age|1957|11|05}} | birth_place = Strängnäs, Sweden | nationality = Swedish | occupation = Nephrologist and academic | title = | awards = | website = | education = M.D. Medicine<br>Ph.D. Nephrology | alma_mater = Karolinska In...'
 
Filled in 26 bare reference(s) with reFill 2
Line 16: Line 16:
| workplaces = [[Karolinska University Hospital]]<br>Karolinska Institutet
| workplaces = [[Karolinska University Hospital]]<br>Karolinska Institutet
}}
}}
'''Peter Stenvinkel''' is a Swedish [[Nephrology|nephrologist]] and academic. He is a senior lecturer at [[Karolinska University Hospital]] and a professor of [[nephrology]] at [[Karolinska Institutet]].<ref>{{cite web|url=https://education.freseniusmedicalcare.com/w/presenters/6200-peter-stenvinkel-md-phd|title=Peter Stenvinkel, MD, PhD}}</ref>
'''Peter Stenvinkel''' is a Swedish [[Nephrology|nephrologist]] and academic. He is a senior lecturer at [[Karolinska University Hospital]] and a professor of [[nephrology]] at [[Karolinska Institutet]].<ref>{{Cite web|url=https://education.freseniusmedicalcare.com/w/presenters/6200-peter-stenvinkel-md-phd|title=Our presenters - Presenters - Fresenius Medical Care Global Medical Information and Education Group|website=education.freseniusmedicalcare.com}}</ref>


Stenvinkel has conducted [[translational research]] aimed at identifying risk factors for metabolic, cardiovascular, and nutritional complications in [[chronic kidney disease]] (CKD). His work has delved into various aspects of [[inflammation]], [[wasting]], and [[metabolism]] in CKD patients. For his contributions to the field of renal medicine, he has won the Karolina Price, Vizenca Price,<ref name=ggs>{{cite web|url=https://theconversation.com/profiles/peter-stenvinkel-1479075|title=Peter Stenvinkel Professor of Nephrology, Karolinska Institutet}}</ref> Addis Gold Medal and the ERA-EDTA prize for outstanding educational activities.<ref name=ssq>{{cite web|url=https://www.era-online.org/about-us/governance/era-awards/past-era-awardees/|title=Past ERA Awardees}}</ref>
Stenvinkel has conducted [[translational research]] aimed at identifying risk factors for metabolic, cardiovascular, and nutritional complications in [[chronic kidney disease]] (CKD). His work has delved into various aspects of [[inflammation]], [[wasting]], and [[metabolism]] in CKD patients. For his contributions to the field of renal medicine, he has won the Karolina Price, Vizenca Price,<ref name=ggs>{{Cite web|url=https://theconversation.com/profiles/peter-stenvinkel-1479075|title=Peter Stenvinkel|date=October 12, 2023|website=The Conversation}}</ref> Addis Gold Medal and the ERA-EDTA prize for outstanding educational activities.<ref name=ssq>{{Cite web|url=https://www.era-online.org/about-us/governance/era-awards/past-era-awardees/|title=Past ERA Awardees- Leading European Nephrology}}</ref>


Stenvinkel is an Honorary member of the [[Polish Society of Nephrology]],<ref>{{cite web|url=https://giornaleitalianodinefrologia.it/wp-content/uploads/sites/3/2018/01/12-Rutkowski.pdf|title=History of the Polish Society of Nephrology}}</ref> as well as the Australian and New Zealand Society of Nephrology. He served as an Editor-in-chief for ''NDT-E'' and has served as Editor for the ''[[Journal of Internal Medicine]]'' since 2022.<ref>{{cite web|url=https://onlinelibrary.wiley.com/page/journal/13652796/homepage/jim_editors.htm|title=JIM Editors}}</ref>
Stenvinkel is an Honorary member of the [[Polish Society of Nephrology]],<ref>{{cite web|url=https://giornaleitalianodinefrologia.it/wp-content/uploads/sites/3/2018/01/12-Rutkowski.pdf|title=History of the Polish Society of Nephrology}}</ref> as well as the Australian and New Zealand Society of Nephrology. He served as an Editor-in-chief for ''NDT-E'' and has served as Editor for the ''[[Journal of Internal Medicine]]'' since 2022.<ref>{{Cite web|url=https://onlinelibrary.wiley.com/page/journal/13652796/homepage/jim_editors.htm|title=Journal of Internal Medicine}}</ref>


==Education==
==Education==
Line 26: Line 26:


==Career==
==Career==
Stenvinkel began his academic career as an Associate Professor at Karolinska Institutet in 1997. Since 2009, he has been serving as a Professor of Nephrology at Karolinska Institutet and Senior lecturer at Karolinska University Hospital and where he engages in clinical duties, research, and administration.<ref>{{cite web|url=https://www.intricare.eu/project_supervisors/peter_stenvinkel.html|title=Peter Stenvinkel}}</ref>
Stenvinkel began his academic career as an Associate Professor at Karolinska Institutet in 1997. Since 2009, he has been serving as a Professor of Nephrology at Karolinska Institutet and Senior lecturer at Karolinska University Hospital and where he engages in clinical duties, research, and administration.<ref>{{Cite web|url=https://www.intricare.eu/project_supervisors/peter_stenvinkel.html|title=Project supervisors - Peter Stenvinkel &#124; INTRICARE|website=www.intricare.eu}}</ref>


Stenvinkel was a member of the KDOQI working group on risk factors for [[Cardiovascular disease|CVD]] in [[Chronic kidney disease|CKD]] from 2001 to 2004 and also on multiple advisory boards, including the [[Gambro]] Advisory Board, the Scientific Advisory Board of ERA-EDTA, and the [[Baxter International|Baxter]] Medical Advisory Board until 2013.<ref>{{cite web|url=https://kidneyfoundation.cachefly.net/professionals/KDOQI/guidelines_cvd/bio.htm|title=KDOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients}}</ref>
Stenvinkel was a member of the KDOQI working group on risk factors for [[Cardiovascular disease|CVD]] in [[Chronic kidney disease|CKD]] from 2001 to 2004 and also on multiple advisory boards, including the [[Gambro]] Advisory Board, the Scientific Advisory Board of ERA-EDTA, and the [[Baxter International|Baxter]] Medical Advisory Board until 2013.<ref>{{Cite web|url=https://kidneyfoundation.cachefly.net/professionals/KDOQI/guidelines_cvd/bio.htm|title=NKF KDOQI Guidelines|website=kidneyfoundation.cachefly.net}}</ref>


==Research==
==Research==
Line 34: Line 34:


===Nephrology and cardiovascular disease===
===Nephrology and cardiovascular disease===
Stenvinkel's research has focused on the need for effective interventions addressing cardiovascular and nutritional complications in chronic kidney disease (CKD). In one of his highly cited studies, he explored the correlation between malnutrition, inflammation, and atherosclerosis to delve into their collective impact on cardiovascular disease (CVD) development in CKD patients, suggesting a synergistic effect in promoting atherosclerosis.<ref>{{cite web|url=https://www.sciencedirect.com/science/article/pii/S0085253815461460|title=Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure}}</ref> Discussing chronic inflammation in CKD patients, he proposed a classification system for two types of malnutrition in CKD,<ref>{{cite web|url=https://academic.oup.com/ndt/article/15/7/953/1810799?login=false|title=Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation, and atherosclerosis (MIA syndrome)}}</ref> and expanded on the relationship between inflammation and malnutrition by presenting the hypothesis that increased oxidative stress significantly influences CVD development in uremic patients.<ref>{{cite web|url=https://www.sciencedirect.com/science/article/pii/S0085253815487095|title=The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia}}</ref> He showed that inflammation acts as a catalyst and changes the risk factor profile<ref>{{cite web|url=https://journals.lww.com/CJASN/Fulltext/2009/12001/Persistent_Inflammation_as_a_Catalyst_for_Other.9.aspx|title=Persistent Inflammation as a Catalyst for Other Risk Factors in Chronic Kidney Disease}}</ref> and also contributed to a technical note emphasizing the complexity of uremic retention, highlighting the need for comprehensive analytical methods beyond traditional markers like urea and creatinine.<ref>{{cite web|url=https://www.sciencedirect.com/science/article/pii/S008525381549088X|title=Review on uremic toxins: Classification, concentration, and interindividual variability}}</ref>
Stenvinkel's research has focused on the need for effective interventions addressing cardiovascular and nutritional complications in chronic kidney disease (CKD). In one of his highly cited studies, he explored the correlation between malnutrition, inflammation, and atherosclerosis to delve into their collective impact on cardiovascular disease (CVD) development in CKD patients, suggesting a synergistic effect in promoting atherosclerosis.<ref>{{Cite journal|url=https://www.sciencedirect.com/science/article/pii/S0085253815461460|title=Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure|first1=Peter|last1=Stenvinkel|first2=Olof|last2=Heimbürger|first3=Furcy|last3=Paultre|first4=Ulf|last4=Diczfalusy|first5=Tao|last5=Wang|first6=Lars|last6=Berglund|first7=Tomas|last7=Jogestrand|date=May 1, 1999|journal=Kidney International|volume=55|issue=5|pages=1899–1911|via=ScienceDirect|doi=10.1046/j.1523-1755.1999.00422.x}}</ref> Discussing chronic inflammation in CKD patients, he proposed a classification system for two types of malnutrition in CKD,<ref>{{cite web|url=https://academic.oup.com/ndt/article/15/7/953/1810799?login=false|title=Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation, and atherosclerosis (MIA syndrome)}}</ref> and expanded on the relationship between inflammation and malnutrition by presenting the hypothesis that increased oxidative stress significantly influences CVD development in uremic patients.<ref>{{Cite journal|url=https://www.sciencedirect.com/science/article/pii/S0085253815487095|title=The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia|first1=Jonathan|last1=Himmelfarb|first2=Peter|last2=Stenvinkel|first3=T. Alp|last3=Ikizler|first4=Raymond M.|last4=Hakim|date=November 1, 2002|journal=Kidney International|volume=62|issue=5|pages=1524–1538|via=ScienceDirect|doi=10.1046/j.1523-1755.2002.00600.x}}</ref> He showed that inflammation acts as a catalyst and changes the risk factor profile<ref>{{Cite journal|url=https://journals.lww.com/CJASN/Fulltext/2009/12001/Persistent_Inflammation_as_a_Catalyst_for_Other.9.aspx|title=Persistent Inflammation as a Catalyst for Other Risk Factors in Chronic Kidney Disease: A Hypothesis Proposal|first1=Juan Jesús|last1=Carrero|first2=Peter|last2=Stenvinkel|date=December 8, 2009|journal=Clinical Journal of the American Society of Nephrology|volume=4|issue=Supplement_1|pages=S49|via=journals.lww.com|doi=10.2215/CJN.02720409}}</ref> and also contributed to a technical note emphasizing the complexity of uremic retention, highlighting the need for comprehensive analytical methods beyond traditional markers like urea and creatinine.<ref>{{Cite journal|url=https://www.sciencedirect.com/science/article/pii/S008525381549088X|title=Review on uremic toxins: Classification, concentration, and interindividual variability|date=May 1, 2003|journal=Kidney International|volume=63|issue=5|pages=1934–1943|via=ScienceDirect|doi=10.1046/j.1523-1755.2003.00924.x}}</ref>


Among other highly cited works, Stenvinkel's collaborative research explored the role of oxidative stress in CKD, focusing on its impact on CVD morbidity and mechanisms leading to enhanced oxidative stress in CKD.<ref>{{cite web|url=https://academic.oup.com/ndt/article/18/7/1272/1809799|title=Oxidative stress in end‐stage renal disease: an emerging threat to patient outcome}}</ref> Additionally, he investigated how dysregulated cytokine networks contributed to accelerated atherosclerosis, resulting in increased inflammation risk in CKD patients,<ref>{{cite web|url=https://www.sciencedirect.com/science/article/pii/S0085253815505784|title=IL-10, IL-6, and TNF-α: Central factors in the altered cytokine network of uremia The good, the bad, and the ugly}}</ref> as well as demonstrated a link between immune dysfunction, CVD, and infections, leading to mortality in ESRD patients.<ref>{{cite web|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4571158/|title=Aspects of Immune Dysfunction in End-stage Renal Disease}}</ref> In 2002, he show that IL-6 is a predictor of mortality in CKD which was evidenced by his study on end-stage renal disease (ESRD) patients at the outset of dialysis treatment.<ref>{{cite web|url=https://academic.oup.com/ndt/article/17/9/1684/1904119|title=Interleukin‐6 is an independent predictor of mortality in patients starting dialysis treatment}}</ref>
Among other highly cited works, Stenvinkel's collaborative research explored the role of oxidative stress in CKD, focusing on its impact on CVD morbidity and mechanisms leading to enhanced oxidative stress in CKD.<ref>{{cite web|url=https://academic.oup.com/ndt/article/18/7/1272/1809799|title=Oxidative stress in end‐stage renal disease: an emerging threat to patient outcome}}</ref> Additionally, he investigated how dysregulated cytokine networks contributed to accelerated atherosclerosis, resulting in increased inflammation risk in CKD patients,<ref>{{Cite journal|url=https://www.sciencedirect.com/science/article/pii/S0085253815505784|title=IL-10, IL-6, and TNF-α: Central factors in the altered cytokine network of uremia—The good, the bad, and the ugly|first1=Peter|last1=Stenvinkel|first2=Markus|last2=Ketteler|first3=Richard J.|last3=Johnson|first4=Bengt|last4=Lindholm|first5=Roberto|last5=Pecoits-Filho|first6=Miguel|last6=Riella|first7=Olof|last7=Heimbürger|first8=Tommy|last8=Cederholm|first9=Matthias|last9=Girndt|date=April 1, 2005|journal=Kidney International|volume=67|issue=4|pages=1216–1233|via=ScienceDirect|doi=10.1111/j.1523-1755.2005.00200.x}}</ref> as well as demonstrated a link between immune dysfunction, CVD, and infections, leading to mortality in ESRD patients.<ref>{{Cite journal|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4571158/|title=Aspects of Immune Dysfunction in End-stage Renal Disease|first1=Sawako|last1=Kato|first2=Michal|last2=Chmielewski|first3=Hirokazu|last3=Honda|first4=Roberto|last4=Pecoits-Filho|first5=Seiichi|last5=Matsuo|first6=Yukio|last6=Yuzawa|first7=Anders|last7=Tranaeus|first8=Peter|last8=Stenvinkel|first9=Bengt|last9=Lindholm|date=September 8, 2008|journal=Clinical Journal of the American Society of Nephrology : CJASN|volume=3|issue=5|pages=1526–1533|via=PubMed Central|doi=10.2215/CJN.00950208|pmid=18701615|pmc=4571158}}</ref> In 2002, he show that IL-6 is a predictor of mortality in CKD which was evidenced by his study on end-stage renal disease (ESRD) patients at the outset of dialysis treatment.<ref>{{cite web|url=https://academic.oup.com/ndt/article/17/9/1684/1904119|title=Interleukin‐6 is an independent predictor of mortality in patients starting dialysis treatment}}</ref>


Stenvinkel was part of the consortium, which identified sixteen novel genetic loci associated with blood pressure regulation, offering insights and potential therapeutic pathways for cardiovascular disease prevention.<ref>{{cite web|url=https://www.nature.com/articles/nature10405|title=Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk}}</ref> He has examined the bidirectional association between CKD and CVD, emphasizing the challenges in identifying cardiovascular culprits due to paradoxical associations and suggesting the potential role of proteomics and epigenetics in understanding vascular risk factors.<ref>{{cite web|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631093/|title=Emerging Biomarkers for Evaluating Cardiovascular Risk in the Chronic Kidney Disease Patient: How Do New Pieces Fit into the Uremic Puzzle?}}</ref> He also addressed the overlooked epidemic of CKD and its association with CVD to emphasize early diagnosis through proteinuria.<ref>{{cite web|url=https://onlinelibrary.wiley.com/doi/full/10.1111/j.1365-2796.2010.02269.x|title=Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease}}</ref> In recent years his research highlighted the premature aging,<ref>{{cite web|url=https://www.nature.com/articles/nrneph.2014.185|title=Chronic kidney disease and premature ageing}}</ref> and accelerated vascular aging in the toxic uremic milieu,<ref>{{cite web|url=https://pubmed.ncbi.nlm.nih.gov/37053277/|title=Accelerated Vascular Aging in Chronic Kidney Disease: The Potential for Novel Therapies}}</ref> as well as advocated for interdisciplinary collaboration for innovative CKD treatments using insights from diverse species.<ref>{{cite web|url=https://www.nature.com/articles/nrneph.2017.169|title=Novel treatment strategies for chronic kidney disease: insights from the animal kingdom}}</ref> In related research, he advocated for the concept of "food as medicine" in metabolic diseases like CKD, emphasizing dietary interventions, as bioactive nutrients have shown promise in mitigating CKD-related features.<ref>{{cite web|url=https://www.nature.com/articles/s41581-020-00345-8|title=Food as medicine: targeting the uraemic phenotype in chronic kidney disease}}</ref>
Stenvinkel was part of the consortium, which identified sixteen novel genetic loci associated with blood pressure regulation, offering insights and potential therapeutic pathways for cardiovascular disease prevention.<ref>{{Cite journal|url=https://www.nature.com/articles/nature10405|title=Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk|date=October 8, 2011|journal=Nature|volume=478|issue=7367|pages=103–109|via=www.nature.com|doi=10.1038/nature10405}}</ref> He has examined the bidirectional association between CKD and CVD, emphasizing the challenges in identifying cardiovascular culprits due to paradoxical associations and suggesting the potential role of proteomics and epigenetics in understanding vascular risk factors.<ref>{{Cite journal|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6631093/|title=Emerging Biomarkers for Evaluating Cardiovascular Risk in the Chronic Kidney Disease Patient: How Do New Pieces Fit into the Uremic Puzzle?|first1=Peter|last1=Stenvinkel|first2=Juan Jesu’s|last2=Carrero|first3=Jonas|last3=Axelsson|first4=Bengt|last4=Lindholm|first5=Olof|last5=Heimbürger|first6=Ziad|last6=Massy|date=March 8, 2008|journal=Clinical Journal of the American Society of Nephrology : CJASN|volume=3|issue=2|pages=505–521|via=PubMed Central|doi=10.2215/CJN.03670807|pmid=18184879|pmc=6631093}}</ref> He also addressed the overlooked epidemic of CKD and its association with CVD to emphasize early diagnosis through proteinuria.<ref>{{Cite journal|url=https://onlinelibrary.wiley.com/doi/10.1111/j.1365-2796.2010.02269.x|title=Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease|first=P.|last=Stenvinkel|date=November 8, 2010|journal=Journal of Internal Medicine|volume=268|issue=5|pages=456–467|via=CrossRef|doi=10.1111/j.1365-2796.2010.02269.x}}</ref> In recent years his research highlighted the premature aging,<ref>{{Cite journal|url=https://www.nature.com/articles/nrneph.2014.185|title=Chronic kidney disease and premature ageing|first1=Jeroen P.|last1=Kooman|first2=Peter|last2=Kotanko|first3=Annemie M. W. J.|last3=Schols|first4=Paul G.|last4=Shiels|first5=Peter|last5=Stenvinkel|date=December 8, 2014|journal=Nature Reviews Nephrology|volume=10|issue=12|pages=732–742|via=www.nature.com|doi=10.1038/nrneph.2014.185}}</ref> and accelerated vascular aging in the toxic uremic milieu,<ref>{{Cite journal|url=https://pubmed.ncbi.nlm.nih.gov/37053277/|title=Accelerated Vascular Aging in Chronic Kidney Disease: The Potential for Novel Therapies|first1=S.|last1=Hobson|first2=S.|last2=Arefin|first3=A.|last3=Witasp|first4=L.|last4=Hernandez|first5=K.|last5=Kublickiene|first6=P. G.|last6=Shiels|first7=P.|last7=Stenvinkel|date=April 14, 2023|journal=Circulation Research|volume=132|issue=8|pages=950–969|via=PubMed|doi=10.1161/CIRCRESAHA.122.321751|pmid=37053277}}</ref> as well as advocated for interdisciplinary collaboration for innovative CKD treatments using insights from diverse species.<ref>{{Cite journal|url=https://www.nature.com/articles/nrneph.2017.169|title=Novel treatment strategies for chronic kidney disease: insights from the animal kingdom|first1=Peter|last1=Stenvinkel|first2=Johanna|last2=Painer|first3=Makoto|last3=Kuro-o|first4=Miguel|last4=Lanaspa|first5=Walter|last5=Arnold|first6=Thomas|last6=Ruf|first7=Paul G.|last7=Shiels|first8=Richard J.|last8=Johnson|date=April 8, 2018|journal=Nature Reviews Nephrology|volume=14|issue=4|pages=265–284|via=www.nature.com|doi=10.1038/nrneph.2017.169}}</ref> In related research, he advocated for the concept of "food as medicine" in metabolic diseases like CKD, emphasizing dietary interventions, as bioactive nutrients have shown promise in mitigating CKD-related features.<ref>{{Cite journal|url=https://www.nature.com/articles/s41581-020-00345-8|title=Food as medicine: targeting the uraemic phenotype in chronic kidney disease|first1=Denise|last1=Mafra|first2=Natalia A.|last2=Borges|first3=Bengt|last3=Lindholm|first4=Paul G.|last4=Shiels|first5=Pieter|last5=Evenepoel|first6=Peter|last6=Stenvinkel|date=March 8, 2021|journal=Nature Reviews Nephrology|volume=17|issue=3|pages=153–171|via=www.nature.com|doi=10.1038/s41581-020-00345-8}}</ref>


Stenvinkel was part of the group that standardized the terminology for muscle wasting, malnutrition, and inflammation in CKD and AKI, and introduced "protein-energy wasting (PEW)" to describe loss of body protein mass and fuel reserves.<ref>{{cite web|url=https://www.sciencedirect.com/science/article/pii/S0085253815529992|title=A proposed nomenclature and diagnostic criteria for protein–energy wasting in acute and chronic kidney disease}}</ref> He researched PEW in CKD patients, outlining its multifactorial etiology, including insufficient food intake, uremia-induced alterations, inflammation, acidosis, comorbidities<ref>{{cite web|url=https://www.sciencedirect.com/science/article/pii/S105122761300006X|title=Etiology of the Protein-Energy Wasting Syndrome in Chronic Kidney Disease: A Consensus Statement From the International Society of Renal Nutrition and Metabolism (ISRNM)}}</ref> and addressed interventions for PEW underscoring the effectiveness of nutritional supplementation and emerging therapies like anabolic agents.<ref>{{cite web|url=https://www.sciencedirect.com/science/article/pii/S0085253815560973|title=Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism}}</ref>
Stenvinkel was part of the group that standardized the terminology for muscle wasting, malnutrition, and inflammation in CKD and AKI, and introduced "protein-energy wasting (PEW)" to describe loss of body protein mass and fuel reserves.<ref>{{Cite journal|url=https://www.sciencedirect.com/science/article/pii/S0085253815529992|title=A proposed nomenclature and diagnostic criteria for protein–energy wasting in acute and chronic kidney disease|first1=D.|last1=Fouque|first2=K.|last2=Kalantar-Zadeh|first3=J.|last3=Kopple|first4=N.|last4=Cano|first5=P.|last5=Chauveau|first6=L.|last6=Cuppari|first7=H.|last7=Franch|first8=G.|last8=Guarnieri|first9=T. A.|last9=Ikizler|first10=G.|last10=Kaysen|first11=B.|last11=Lindholm|first12=Z.|last12=Massy|first13=W.|last13=Mitch|first14=E.|last14=Pineda|first15=P.|last15=Stenvinkel|first16=A.|last16=Trevinho-Becerra|first17=C.|last17=Wanner|date=February 2, 2008|journal=Kidney International|volume=73|issue=4|pages=391–398|via=ScienceDirect|doi=10.1038/sj.ki.5002585}}</ref> He researched PEW in CKD patients, outlining its multifactorial etiology, including insufficient food intake, uremia-induced alterations, inflammation, acidosis, comorbidities<ref>{{Cite journal|url=https://www.sciencedirect.com/science/article/pii/S105122761300006X|title=Etiology of the Protein-Energy Wasting Syndrome in Chronic Kidney Disease: A Consensus Statement From the International Society of Renal Nutrition and Metabolism (ISRNM)|first1=Juan Jesús|last1=Carrero|first2=Peter|last2=Stenvinkel|first3=Lilian|last3=Cuppari|first4=T. Alp|last4=Ikizler|first5=Kamyar|last5=Kalantar-Zadeh|first6=George|last6=Kaysen|first7=William E.|last7=Mitch|first8=S. Russ|last8=Price|first9=Christoph|last9=Wanner|first10=Angela Y. M.|last10=Wang|first11=Pieter|last11=ter Wee|first12=Harold A.|last12=Franch|date=March 1, 2013|journal=Journal of Renal Nutrition|volume=23|issue=2|pages=77–90|via=ScienceDirect|doi=10.1053/j.jrn.2013.01.001}}</ref> and addressed interventions for PEW underscoring the effectiveness of nutritional supplementation and emerging therapies like anabolic agents.<ref>{{Cite journal|url=https://www.sciencedirect.com/science/article/pii/S0085253815560973|title=Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism|first1=T.|last1=Alp Ikizler|first2=Noel J.|last2=Cano|first3=Harold|last3=Franch|first4=Denis|last4=Fouque|first5=Jonathan|last5=Himmelfarb|first6=Kamyar|last6=Kalantar-Zadeh|first7=Martin K.|last7=Kuhlmann|first8=Peter|last8=Stenvinkel|first9=Pieter|last9=TerWee|first10=Daniel|last10=Teta|first11=Angela Yee-Moon|last11=Wang|first12=Christoph|last12=Wanner|date=December 1, 2013|journal=Kidney International|volume=84|issue=6|pages=1096–1107|via=ScienceDirect|doi=10.1038/ki.2013.147}}</ref>


===Planetary health===
===Planetary health===
Stenvinkel's research in planetary health has examined how environmental and climate threats have triggered processes like inflammation, oxidative stress, and mitochondrial dysfunction, reshaping disease patterns and increasing the risk of chronic conditions such as dementia, obesity, and diabetes.<ref>{{cite web|url=https://staff.ki.se/interview-with-peter-stenvinkel|title=Interview with Peter Stenvinkel}}</ref> His work has also endorsed more sustainable healthcare practices, including reconsidering food production and consumption,<ref>{{cite web|url=https://www.cambridge.org/core/journals/journal-of-clinical-and-translational-science/article/biomimetics-provide-lessons-from-nature-for-contemporary-ways-to-improve-human-health/46B044BFED510A02FA8D1BE9361760E4|title=Biomimetics provides lessons from nature for contemporary ways to improve human health}}</ref> and has suggested the use of interdisciplinary collaboration, biomimetic organizational models, and nature-inspired solutions in mitigating climate change as strategies to address environmental degradation and biodiversity loss.<ref>{{cite web|url=https://www.sciencedirect.com/science/article/pii/S0301479722025543|title=Lessons from evolution by natural selection: An unprecedented opportunity to use biomimetics to improve planetary health}}</ref> In 2024, he published a Swedish science book on ''Nature´s Intelligence'' and has published science texts on the link between animal hibernation and aging.<ref>{{cite web|url=https://theconversation.com/the-curious-link-between-animal-hibernation-and-ageing-and-what-humans-could-learn-from-it-218871|title=The curious link between animal hibernation and ageing – and what humans could learn from it}}</ref>
Stenvinkel's research in planetary health has examined how environmental and climate threats have triggered processes like inflammation, oxidative stress, and mitochondrial dysfunction, reshaping disease patterns and increasing the risk of chronic conditions such as dementia, obesity, and diabetes.<ref>{{Cite web|url=https://staff.ki.se/interview-with-peter-stenvinkel|title=Interview with Peter Stenvinkel &#124; Staff Portal|website=staff.ki.se}}</ref> His work has also endorsed more sustainable healthcare practices, including reconsidering food production and consumption,<ref>{{Cite journal|url=https://www.cambridge.org/core/journals/journal-of-clinical-and-translational-science/article/biomimetics-provide-lessons-from-nature-for-contemporary-ways-to-improve-human-health/46B044BFED510A02FA8D1BE9361760E4|title=Biomimetics provides lessons from nature for contemporary ways to improve human health|first1=Peter|last1=Stenvinkel|first2=Carla M.|last2=Avesani|first3=Line J.|last3=Gordon|first4=Martin|last4=Schalling|first5=Paul G.|last5=Shiels|date=January 8, 2021|journal=Journal of Clinical and Translational Science|volume=5|issue=1|pages=e128|via=Cambridge University Press|doi=10.1017/cts.2021.790}}</ref> and has suggested the use of interdisciplinary collaboration, biomimetic organizational models, and nature-inspired solutions in mitigating climate change as strategies to address environmental degradation and biodiversity loss.<ref>{{Cite journal|url=https://www.sciencedirect.com/science/article/pii/S0301479722025543|title=Lessons from evolution by natural selection: An unprecedented opportunity to use biomimetics to improve planetary health|first1=Peter|last1=Stenvinkel|first2=Paul G.|last2=Shiels|first3=Richard J.|last3=Johnson|date=February 15, 2023|journal=Journal of Environmental Management|volume=328|pages=116981|via=ScienceDirect|doi=10.1016/j.jenvman.2022.116981}}</ref> In 2024, he published a Swedish science book on ''Nature´s Intelligence'' and has published science texts on the link between animal hibernation and aging.<ref>{{Cite web|url=http://theconversation.com/the-curious-link-between-animal-hibernation-and-ageing-and-what-humans-could-learn-from-it-218871|title=The curious link between animal hibernation and ageing – and what humans could learn from it|first=Peter|last=Stenvinkel|date=January 5, 2024|website=The Conversation}}</ref>


==Awards and honors==
==Awards and honors==

Revision as of 06:55, 8 March 2024

Peter Stenvinkel
Born (1957-11-05) November 5, 1957 (age 66)
Strängnäs, Sweden
NationalitySwedish
Occupation(s)Nephrologist and academic
Academic background
EducationM.D. Medicine
Ph.D. Nephrology
Alma materKarolinska Institutet
Academic work
InstitutionsKarolinska University Hospital
Karolinska Institutet

Peter Stenvinkel is a Swedish nephrologist and academic. He is a senior lecturer at Karolinska University Hospital and a professor of nephrology at Karolinska Institutet.[1]

Stenvinkel has conducted translational research aimed at identifying risk factors for metabolic, cardiovascular, and nutritional complications in chronic kidney disease (CKD). His work has delved into various aspects of inflammation, wasting, and metabolism in CKD patients. For his contributions to the field of renal medicine, he has won the Karolina Price, Vizenca Price,[2] Addis Gold Medal and the ERA-EDTA prize for outstanding educational activities.[3]

Stenvinkel is an Honorary member of the Polish Society of Nephrology,[4] as well as the Australian and New Zealand Society of Nephrology. He served as an Editor-in-chief for NDT-E and has served as Editor for the Journal of Internal Medicine since 2022.[5]

Education

Stenvinkel earned his Doctor of Medicine degree from Karolinska Institute in 1982. While working as a Specialist in Nephrology, he graduated with a doctoral degree in Renal Medicine in 1994.[6]

Career

Stenvinkel began his academic career as an Associate Professor at Karolinska Institutet in 1997. Since 2009, he has been serving as a Professor of Nephrology at Karolinska Institutet and Senior lecturer at Karolinska University Hospital and where he engages in clinical duties, research, and administration.[7]

Stenvinkel was a member of the KDOQI working group on risk factors for CVD in CKD from 2001 to 2004 and also on multiple advisory boards, including the Gambro Advisory Board, the Scientific Advisory Board of ERA-EDTA, and the Baxter Medical Advisory Board until 2013.[8]

Research

Stenvinkel has conducted translational research, emphasizing risk factors for metabolic, cardiovascular, and nutritional complications in chronic kidney disease (CKD).

Nephrology and cardiovascular disease

Stenvinkel's research has focused on the need for effective interventions addressing cardiovascular and nutritional complications in chronic kidney disease (CKD). In one of his highly cited studies, he explored the correlation between malnutrition, inflammation, and atherosclerosis to delve into their collective impact on cardiovascular disease (CVD) development in CKD patients, suggesting a synergistic effect in promoting atherosclerosis.[9] Discussing chronic inflammation in CKD patients, he proposed a classification system for two types of malnutrition in CKD,[10] and expanded on the relationship between inflammation and malnutrition by presenting the hypothesis that increased oxidative stress significantly influences CVD development in uremic patients.[11] He showed that inflammation acts as a catalyst and changes the risk factor profile[12] and also contributed to a technical note emphasizing the complexity of uremic retention, highlighting the need for comprehensive analytical methods beyond traditional markers like urea and creatinine.[13]

Among other highly cited works, Stenvinkel's collaborative research explored the role of oxidative stress in CKD, focusing on its impact on CVD morbidity and mechanisms leading to enhanced oxidative stress in CKD.[14] Additionally, he investigated how dysregulated cytokine networks contributed to accelerated atherosclerosis, resulting in increased inflammation risk in CKD patients,[15] as well as demonstrated a link between immune dysfunction, CVD, and infections, leading to mortality in ESRD patients.[16] In 2002, he show that IL-6 is a predictor of mortality in CKD which was evidenced by his study on end-stage renal disease (ESRD) patients at the outset of dialysis treatment.[17]

Stenvinkel was part of the consortium, which identified sixteen novel genetic loci associated with blood pressure regulation, offering insights and potential therapeutic pathways for cardiovascular disease prevention.[18] He has examined the bidirectional association between CKD and CVD, emphasizing the challenges in identifying cardiovascular culprits due to paradoxical associations and suggesting the potential role of proteomics and epigenetics in understanding vascular risk factors.[19] He also addressed the overlooked epidemic of CKD and its association with CVD to emphasize early diagnosis through proteinuria.[20] In recent years his research highlighted the premature aging,[21] and accelerated vascular aging in the toxic uremic milieu,[22] as well as advocated for interdisciplinary collaboration for innovative CKD treatments using insights from diverse species.[23] In related research, he advocated for the concept of "food as medicine" in metabolic diseases like CKD, emphasizing dietary interventions, as bioactive nutrients have shown promise in mitigating CKD-related features.[24]

Stenvinkel was part of the group that standardized the terminology for muscle wasting, malnutrition, and inflammation in CKD and AKI, and introduced "protein-energy wasting (PEW)" to describe loss of body protein mass and fuel reserves.[25] He researched PEW in CKD patients, outlining its multifactorial etiology, including insufficient food intake, uremia-induced alterations, inflammation, acidosis, comorbidities[26] and addressed interventions for PEW underscoring the effectiveness of nutritional supplementation and emerging therapies like anabolic agents.[27]

Planetary health

Stenvinkel's research in planetary health has examined how environmental and climate threats have triggered processes like inflammation, oxidative stress, and mitochondrial dysfunction, reshaping disease patterns and increasing the risk of chronic conditions such as dementia, obesity, and diabetes.[28] His work has also endorsed more sustainable healthcare practices, including reconsidering food production and consumption,[29] and has suggested the use of interdisciplinary collaboration, biomimetic organizational models, and nature-inspired solutions in mitigating climate change as strategies to address environmental degradation and biodiversity loss.[30] In 2024, he published a Swedish science book on Nature´s Intelligence and has published science texts on the link between animal hibernation and aging.[31]

Awards and honors

Selected articles

  • Stenvinkel, P., Heimbürger, O., Paultre, F., Diczfalusy, U., Wang, T., Berglund, L., & Jogestrand, T. (1999). Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney international, 55(5), 1899-1911.
  • Stenvinkel, P., Heimbürger, O., Lindholm, B., Kaysen, G. A., & Bergström, J. (2000). Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrology Dialysis Transplantation, 15(7), 953-960.
  • Himmelfarb, J., Stenvinkel, P., Ikizler, T. A., & Hakim, R. M. (2002). The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney international, 62(5), 1524-1538.
  • Vanholder, R., De Smet, R., Glorieux, G., Argilés, A., Baurmeister, U., Brunet, P., ... & European Uremic Toxin Work Group (EUTox. (2003). Review on uremic toxins: classification, concentration, and interindividual variability. Kidney international, 63(5), 1934-1943.
  • Stenvinkel, P., Ketteler, M., Johnson, R. J., Lindholm, B., Pecoits-Filho, R., Riella, M., ... & Girndt, M. (2005). IL-10, IL-6, and TNF-α: central factors in the altered cytokine network of uremia—the good, the bad, and the ugly. Kidney international, 67(4), 1216-1233.
  • Fouque, D., Kalantar-Zadeh, K., Kopple, J., Cano, N., Chauveau, P., Cuppari, L., ... & Wanner, C. (2008). A proposed nomenclature and diagnostic criteria for protein–energy wasting in acute and chronic kidney disease. Kidney international, 73(4), 391-398.
  • Stenvinkel, P. (2010). Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. Journal of Internal Medicine, 268(5), 456-467.
  • CKDGen Consortium, KidneyGen Consortium, EchoGen consortium, CHARGE-HF consortium, Aspelund, T., Garcia, M., ... & van Gilst, W. H. (2011). Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature, 478(7367), 103-109.
  • Hobson, S., Arefin, S., Witasp, A., Hernandez, L., Kublickiene, K., Shiels, P. G., & Stenvinkel, P. (2023). Accelerated vascular aging in chronic kidney disease: the potential for novel therapies. Circulation Research, 132(8), 950-969.

References

  1. ^ "Our presenters - Presenters - Fresenius Medical Care Global Medical Information and Education Group". education.freseniusmedicalcare.com.
  2. ^ a b "Peter Stenvinkel". The Conversation. October 12, 2023.
  3. ^ a b "Past ERA Awardees- Leading European Nephrology".
  4. ^ "History of the Polish Society of Nephrology" (PDF).
  5. ^ "Journal of Internal Medicine".
  6. ^ "Peter Stenvinkel Professor/Senior Physician".
  7. ^ "Project supervisors - Peter Stenvinkel | INTRICARE". www.intricare.eu.
  8. ^ "NKF KDOQI Guidelines". kidneyfoundation.cachefly.net.
  9. ^ Stenvinkel, Peter; Heimbürger, Olof; Paultre, Furcy; Diczfalusy, Ulf; Wang, Tao; Berglund, Lars; Jogestrand, Tomas (May 1, 1999). "Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure". Kidney International. 55 (5): 1899–1911. doi:10.1046/j.1523-1755.1999.00422.x – via ScienceDirect.
  10. ^ "Are there two types of malnutrition in chronic renal failure? Evidence for relationships between malnutrition, inflammation, and atherosclerosis (MIA syndrome)".
  11. ^ Himmelfarb, Jonathan; Stenvinkel, Peter; Ikizler, T. Alp; Hakim, Raymond M. (November 1, 2002). "The elephant in uremia: Oxidant stress as a unifying concept of cardiovascular disease in uremia". Kidney International. 62 (5): 1524–1538. doi:10.1046/j.1523-1755.2002.00600.x – via ScienceDirect.
  12. ^ Carrero, Juan Jesús; Stenvinkel, Peter (December 8, 2009). "Persistent Inflammation as a Catalyst for Other Risk Factors in Chronic Kidney Disease: A Hypothesis Proposal". Clinical Journal of the American Society of Nephrology. 4 (Supplement_1): S49. doi:10.2215/CJN.02720409 – via journals.lww.com.
  13. ^ "Review on uremic toxins: Classification, concentration, and interindividual variability". Kidney International. 63 (5): 1934–1943. May 1, 2003. doi:10.1046/j.1523-1755.2003.00924.x – via ScienceDirect.
  14. ^ "Oxidative stress in end‐stage renal disease: an emerging threat to patient outcome".
  15. ^ Stenvinkel, Peter; Ketteler, Markus; Johnson, Richard J.; Lindholm, Bengt; Pecoits-Filho, Roberto; Riella, Miguel; Heimbürger, Olof; Cederholm, Tommy; Girndt, Matthias (April 1, 2005). "IL-10, IL-6, and TNF-α: Central factors in the altered cytokine network of uremia—The good, the bad, and the ugly". Kidney International. 67 (4): 1216–1233. doi:10.1111/j.1523-1755.2005.00200.x – via ScienceDirect.
  16. ^ Kato, Sawako; Chmielewski, Michal; Honda, Hirokazu; Pecoits-Filho, Roberto; Matsuo, Seiichi; Yuzawa, Yukio; Tranaeus, Anders; Stenvinkel, Peter; Lindholm, Bengt (September 8, 2008). "Aspects of Immune Dysfunction in End-stage Renal Disease". Clinical Journal of the American Society of Nephrology : CJASN. 3 (5): 1526–1533. doi:10.2215/CJN.00950208. PMC 4571158. PMID 18701615 – via PubMed Central.
  17. ^ "Interleukin‐6 is an independent predictor of mortality in patients starting dialysis treatment".
  18. ^ "Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk". Nature. 478 (7367): 103–109. October 8, 2011. doi:10.1038/nature10405 – via www.nature.com.
  19. ^ Stenvinkel, Peter; Carrero, Juan Jesu’s; Axelsson, Jonas; Lindholm, Bengt; Heimbürger, Olof; Massy, Ziad (March 8, 2008). "Emerging Biomarkers for Evaluating Cardiovascular Risk in the Chronic Kidney Disease Patient: How Do New Pieces Fit into the Uremic Puzzle?". Clinical Journal of the American Society of Nephrology : CJASN. 3 (2): 505–521. doi:10.2215/CJN.03670807. PMC 6631093. PMID 18184879 – via PubMed Central.
  20. ^ Stenvinkel, P. (November 8, 2010). "Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease". Journal of Internal Medicine. 268 (5): 456–467. doi:10.1111/j.1365-2796.2010.02269.x – via CrossRef.
  21. ^ Kooman, Jeroen P.; Kotanko, Peter; Schols, Annemie M. W. J.; Shiels, Paul G.; Stenvinkel, Peter (December 8, 2014). "Chronic kidney disease and premature ageing". Nature Reviews Nephrology. 10 (12): 732–742. doi:10.1038/nrneph.2014.185 – via www.nature.com.
  22. ^ Hobson, S.; Arefin, S.; Witasp, A.; Hernandez, L.; Kublickiene, K.; Shiels, P. G.; Stenvinkel, P. (April 14, 2023). "Accelerated Vascular Aging in Chronic Kidney Disease: The Potential for Novel Therapies". Circulation Research. 132 (8): 950–969. doi:10.1161/CIRCRESAHA.122.321751. PMID 37053277 – via PubMed.
  23. ^ Stenvinkel, Peter; Painer, Johanna; Kuro-o, Makoto; Lanaspa, Miguel; Arnold, Walter; Ruf, Thomas; Shiels, Paul G.; Johnson, Richard J. (April 8, 2018). "Novel treatment strategies for chronic kidney disease: insights from the animal kingdom". Nature Reviews Nephrology. 14 (4): 265–284. doi:10.1038/nrneph.2017.169 – via www.nature.com.
  24. ^ Mafra, Denise; Borges, Natalia A.; Lindholm, Bengt; Shiels, Paul G.; Evenepoel, Pieter; Stenvinkel, Peter (March 8, 2021). "Food as medicine: targeting the uraemic phenotype in chronic kidney disease". Nature Reviews Nephrology. 17 (3): 153–171. doi:10.1038/s41581-020-00345-8 – via www.nature.com.
  25. ^ Fouque, D.; Kalantar-Zadeh, K.; Kopple, J.; Cano, N.; Chauveau, P.; Cuppari, L.; Franch, H.; Guarnieri, G.; Ikizler, T. A.; Kaysen, G.; Lindholm, B.; Massy, Z.; Mitch, W.; Pineda, E.; Stenvinkel, P.; Trevinho-Becerra, A.; Wanner, C. (February 2, 2008). "A proposed nomenclature and diagnostic criteria for protein–energy wasting in acute and chronic kidney disease". Kidney International. 73 (4): 391–398. doi:10.1038/sj.ki.5002585 – via ScienceDirect.
  26. ^ Carrero, Juan Jesús; Stenvinkel, Peter; Cuppari, Lilian; Ikizler, T. Alp; Kalantar-Zadeh, Kamyar; Kaysen, George; Mitch, William E.; Price, S. Russ; Wanner, Christoph; Wang, Angela Y. M.; ter Wee, Pieter; Franch, Harold A. (March 1, 2013). "Etiology of the Protein-Energy Wasting Syndrome in Chronic Kidney Disease: A Consensus Statement From the International Society of Renal Nutrition and Metabolism (ISRNM)". Journal of Renal Nutrition. 23 (2): 77–90. doi:10.1053/j.jrn.2013.01.001 – via ScienceDirect.
  27. ^ Alp Ikizler, T.; Cano, Noel J.; Franch, Harold; Fouque, Denis; Himmelfarb, Jonathan; Kalantar-Zadeh, Kamyar; Kuhlmann, Martin K.; Stenvinkel, Peter; TerWee, Pieter; Teta, Daniel; Wang, Angela Yee-Moon; Wanner, Christoph (December 1, 2013). "Prevention and treatment of protein energy wasting in chronic kidney disease patients: a consensus statement by the International Society of Renal Nutrition and Metabolism". Kidney International. 84 (6): 1096–1107. doi:10.1038/ki.2013.147 – via ScienceDirect.
  28. ^ "Interview with Peter Stenvinkel | Staff Portal". staff.ki.se.
  29. ^ Stenvinkel, Peter; Avesani, Carla M.; Gordon, Line J.; Schalling, Martin; Shiels, Paul G. (January 8, 2021). "Biomimetics provides lessons from nature for contemporary ways to improve human health". Journal of Clinical and Translational Science. 5 (1): e128. doi:10.1017/cts.2021.790 – via Cambridge University Press.
  30. ^ Stenvinkel, Peter; Shiels, Paul G.; Johnson, Richard J. (February 15, 2023). "Lessons from evolution by natural selection: An unprecedented opportunity to use biomimetics to improve planetary health". Journal of Environmental Management. 328: 116981. doi:10.1016/j.jenvman.2022.116981 – via ScienceDirect.
  31. ^ Stenvinkel, Peter (January 5, 2024). "The curious link between animal hibernation and ageing – and what humans could learn from it". The Conversation.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Peter_Stenvinkel&oldid=1212513801"